N083E (Alliance): Long-term outcomes of patients treated in a pilot
phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant
therapy for early stage HER2-positive breast cancer
- Citation:
- Breast Cancer Res Treat vol 182 (3) 613-622
- Year:
- 2020
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 9
- Parents:
- 417
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U10 CA035103, UG1 CA189808, UG1 CA189812, U10 CA035415, U10 CA063849
- Corr. Author:
- Authors:
- Roberto A. Leon-Ferre Edith A Perez David W Hillman Celyne Bueno Alejandra T Perez Beiyun Chen Robert B Jenkins Donald W Northfelt David B Johnson Robert L Carolla Robin T Zon Alvaro Moreno-Aspitia
- Networks:
- FL028, LAPS-MN026, MVCC, NICRC, PR028
- Study
- NCCTG-N083E
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Breast cancer, HER2 cardiac, Gastrointestinal, Tolerability, Lapatinib, Adjuvant